课题基金 / 基金详情

Molecular and Structural Studies of Antibody Diversity Mechanisms

Molecular and Structural Studies of Antibody Diversity Mechanisms
抗体多样性机制的分子和结构研究
批准号:
10242126
负责人:
Vaughn Vasil Smider
金额:
$39.94万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-30 至 2023-07-31

项目摘要

项目成果

Vaughn Vasil Smider的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract Antibodies are extremely important as the primary mediators of the immune response to infectious agents and vaccines, but also as recombinant molecules used as therapeutics, diagnostics, and research reagents. Thus, understanding the mechanisms by which antibodies form, bind, and neutralize their targets is very important in multiple biomedical areas. Most vertebrate antibody repertoires form their diversity through V(D)J recombination, where combinatorial rearrangement of V, D, and J genes form a vast repertoire where the complementarity determining regions (CDRs) form a relatively flat binding surface for interaction with antigen. Remarkably, cows appear to have a different mechanism for generating diversity and binding antigen; cow antibodies have particularly long CDR H3 regions, a subset of which can be over 70 amino acids long, which form -ribbon “stalk” and disulfide-bonded “knob” minidomains that protrude far from the typical antibody surface. Remarkably, antibodies from this repertoire can potently and broadly neutralize HIV, whereas normal human or mouse antibody repertoires cannot. Therefore, they have unique abilities to bind and neutralize particularly challenging antigens. Here we propose studies to understand in molecular detail the genetic mechanisms underlying formation of these antibodies, the binding properties of the stalk and knob minidomains, and the unique potential of these antibodes to bind bivalently and bispecifically. These studies will provide insight into mechanisms of viral neutralization generally, and particularly HIV neutralization. Additionally, given the potential of these antibodies to bind recessed epitopes, we will generate additional antibodies against particularly challenging antigens like enzymatic active sites and ion channels. We will employ mutagenesis, binding, and structural methods, as well as cellular assays to evaluate the unique properties of these antibodies. Understanding this novel class of antibodies in detail could provide fundamental insights needed for effective vaccine design as well as discovery and engineering of antibodies against some of the most challenging targets in biomedicine. Similarly, our unique antibodies discovered and characterized in this proposal could eventually become therapeutic candidates themselves.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3389/fimmu.2021.742418
发表时间: 2021
期刊: Frontiers in immunology
影响因子: 7.3
作者: [Pekar L, Klewinghaus D, Arras P, Carrara SC, Harwardt J, Krah S, Yanakieva D, Toleikis L, Smider VV, Kolmar H, Zielonka S]
通讯作者: Zielonka S
DOI: 10.1038/nature23301
发表时间: 2017-08-03
期刊: Nature
影响因子: 64.8
作者: [Sok D, Le KM, Vadnais M, Saye-Francisco KL, Jardine JG, Torres JL, Berndsen ZT, Kong L, Stanfield R, Ruiz J, Ramos A, Liang CH, Chen PL, Criscitiello MF, Mwangi W, Wilson IA, Ward AB, Smider VV, Burton DR]
通讯作者: Burton DR
DOI: 10.4049/jimmunol.2200455
发表时间: 2022-12-01
期刊: JOURNAL OF IMMUNOLOGY
影响因子: 4.4
作者: [Jenkins, Gabrielle Warner, Safonova, Yana, V. Smider, Vaughn]
通讯作者: V. Smider, Vaughn
DOI: 10.1007/s00251-023-01305-9
发表时间: 2023-08
期刊: IMMUNOGENETICS
影响因子: 3.2
作者: [Ott, Jeannine A. A., Mitchell, Christian, Sheppard, Morgan, Deiss, Thad C. C., Horton, J. M. Cody, Haakenson, Jeremy K. K., Huang, Ruiqi, Kelley, Abigail R. R., Davis, Brian W. W., Derr, James N. N., Smider, Vaughn V. V., Criscitiello, Michael F. F.]
通讯作者: Criscitiello, Michael F. F.
10
    Broadly neutralizing SARS-CoV-2 peptidic knobs
    Ultralong CDR3 antibodies targeting exhausted T cells
    Defining clinically relevant viral epitopes with cow antibodies
    • 批准号:
      9360293
    • 项目类别:
    • 资助金额:
      $37.98万
    • 财政年份:
      2017
    • 负责人:
      Vaughn Vasil Smider
    • 依托单位:
    Defining clinically relevant viral epitopes with cow antibodies
    海外基金